Insurance AdoptionAdoption of NOPAIN or a similar reimbursement model by major commercial insurance plans is probably the biggest linchpin of the investment thesis, but the timing of that is highly uncertain.
NOPAIN ActInvestors looking for an inflection in Exparel sales growth, but this could take longer than hoped as the NOPAIN Act is likely not a 'light switch' nor the 'silver bullet'.
Sales ExpectationsExparel sales missed expectations for the second straight quarter.